Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05732402 · ClinicalTrials.gov registry record · Phase 1
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
A Phase 1 study of Lupus Nephritis and Immunoglobulin A Nephropathy, sponsored by Alpine Immune Sciences.
- Active
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 20
- Study locations
NCT05732402: Active Phase 1 study of Lupus Nephritis and Immunoglobulin A Nephropathy, sponsored by Alpine Immune Sciences.
NCT05732402 is a Phase 1 study of Lupus Nephritis and Immunoglobulin A Nephropathy that is active but no longer recruiting, run by Alpine Immune Sciences. The registered enrollment target is 72 participants, below the 308-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05732402, a Phase 1 study of Lupus Nephritis and Immunoglobulin A Nephropathy, is active but no longer recruiting, sponsored by Alpine Immune Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis - LN), or anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV) to determine if povetacicept is safe and potentially beneficial in treating these diseases. During the study treatment period, participants will receive povetacicept approximately every 4 weeks for 6 months, with the possibility of participating in a 6-month treatment extension period and an optional 52-week treatment extension period. Participants with IgAN and pMN may also receive povetacicept for an additional 52 weeks, if eligible.
Conditions Studied
Interventions
- DRUG Povetacicept
Study Locations (20)
Arizona
- Investigational Site (523) - Phoenix
- Investigational Site (501) - Phoenix
- Investigational Site (524) - Tucson
Texas
- Investigational Site (118) - Colleyville
- Investigational Site (516) - Houston
- Investigational Site (526) - Irving
Florida
- Investigational Site (512) - Orlando
- Investigational Site (525) - Tamarac
New York
- Investigational Site (511) - Albany
- Investigational Site (508) - Brooklyn
California
- Investigational Site (506) - Valencia
Colorado
- Investigational Site (513) - Arvada
Georgia
- Investigational Site (502) - Lawrenceville
Maryland
- The Johns Hopkins University School of Medicine - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2023-03-15 |
| Est. Completion | 2028-03-02 |
| Phase | Phase 1 |
What the registry record for NCT05732402 still lists
NCT05732402 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 308-participant average among 30 other Lupus Nephritis trials with a reported enrollment target (77% lower).
The record links to 4 conditions, with Lupus Nephritis appearing as the primary indexed condition, and to 1 intervention - of which Povetacicept is the first listed.
NCT05732402 names 20 study sites across 14 states, led by Arizona, Texas, Florida.
Frequently Asked Questions
What is clinical trial NCT05732402 about?
NCT05732402 is a clinical study titled "An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases". The goal of this clinical study is to evaluate multiple dose levels of povetacicept in adults with immunoglobulin A (IgA) nephropathy (IgAN), primary membranous nephropathy (pMN), lupus-related kidney disease (lupus nephritis - LN), or anti-neutrophil cytoplasmic antibody (ANCA) associated vasculiti...
What is the current status of trial NCT05732402?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2023-03-15. Estimated completion is 2028-03-02.
What conditions does trial NCT05732402 study?
This clinical trial studies the following conditions: Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis.
What interventions are being tested in trial NCT05732402?
The interventions under investigation include: Povetacicept (DRUG).
Who is sponsoring clinical trial NCT05732402?
This trial is sponsored by Alpine Immune Sciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05732402 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lupus Nephritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05732402's enrollment target sits among peer trials
72 18th of 30 higher than 13 of 30 other Lupus Nephritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lupus Nephritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RECRUITING · Phase 1
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
RECRUITING · Phase 1
-
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
RECRUITING · Phase 1
-
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
RECRUITING · Phase 1
-
A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old
ACTIVE NOT RECRUITING · Phase 1
-
KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI